The company received a regulatory rejection (CRL) for its extended-release JAKAFI formulation in March 2023, causing significant delays and requiring additional studies to satisfy the FDA. Having now addressed the issues, there is heightened pressure on regulatory and commercial teams to ensure a successful launch in 2026.
Filing excerpt
In March 2023, the FDA issued a complete response letter (“CRL”) for ruxolitinib XR tablets for QD use in the treatment of certain types of MF, PV and GVHD.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10kcomplianceBurdenGet every 10-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/456db118-c15c-4e28-a72f-08c4f1beccb5 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "456db118-c15c-4e28-a72f-08c4f1beccb5",
"signal_type": "sec-10k",
"signal_subtype": "complianceBurden",
"detected_at": "2026-02-17T06:34:03.067+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "The company received a regulatory rejection (CRL) for its extended-release JAKAFI formulation in March 2023, causing significant delays and requiring additional studies to satisfy the FDA. Having now addressed the issues, there is heightened pressure on regulatory and commercial teams to ensure a successful launch in 2026.",
"metrics": {
"timeframe": "next_year"
},
"summary": "Incyte addresses FDA Complete Response Letter for JAKAFI XR, targeting mid-2026 launch",
"excerpts": "In March 2023, the FDA issued a complete response letter (“CRL”) for ruxolitinib XR tablets for QD use in the treatment of certain types of MF, PV and GVHD.",
"relevance": 0.8,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
"filing_date": "2026-02-10",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "GRC tools needed",
"signal_category": "risk"
}
}
curl https://signals.autobound.ai/v1/signals/456db118-c15c-4e28-a72f-08c4f1beccb5 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.